Abstract
PMNs incubated with JSLE serum had 11% ( 12.46%) less phagocytosis compared with control serum, see Table 1. Disease activity of each of the 10 clinical episodes was measured using British Isles Lupus Assessment (BILAG) index. There was moderate negative correlation (Spearman’s rank correlation coefficient, r1⁄4 –0.45, P1⁄40.18) between the disease activity scores and the phagocytic activity; 28% of variation in phagocytosis could be explained by BILAG scores, coefficient of determination, r21⁄40.28. Conclusion: JSLE serum reduces the phagocytic ability of healthy neutrophils, whilst patient disease activity had a trend towards moderate negative correlation with this reduction in phagocytosis. To date there is a paucity of data examining the role of neutrophils as phagocytic effectors of E coli in JSLE. As previous work has demonstrated significantly increased levels of apoptotic cells in JSLE patients, future investigation will analyse whether JSLE serum has an effect on the ability of neutrophils to phagocytose apoptotic cells. Funding: This work was supported by Alder Hey NHS Foundation Trust and Lupus UK. Disclosure statement: The author has declared no conflicts of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
